A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer
Small · 2026-07 · 22 (38)
DOI: 10.1002/smll.202514390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 22.03.2026. Verfasst von Min Mu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Onco…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Membrane Proteins, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: China Postdoctoral Science Foundation, Postdoctor Research Fund of West China Hospital, Sichuan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a leading cause of cancer‐related mortality worldwide, with limited efficacy of conventional therapies due to immunosuppressive tumor microenvironments and high recurrence. While bispecific T‐cell engagers (BiTEs) show promise by engaging T cells against tumors, their clinical translation is hindered by poor stability, on‐target off‐tumor effect, and systemic toxicity. Herein, we develop a tumor‐targeted nanozyme (MnO 2 ‐dsDNA@BiTE/APT) that co‐delivers hydrolytically stable double‐strand DNA (dsDNA: a STING agonist) and PD‐L1/CD3 BiTE to overcome these limitations. The nanozyme leverages MnO 2 as a carrier for dsDNA, surface‐loaded with BiTE via polyphenol‐protein coordination, and functionalized with an aptamer (APT) for active targeting. Upon systemic administration, the nanozyme accumulates in tumors, releasing dsDNA, Mn 2+ , and BiTE. The synergistically activates the STING pathway to remodel the immunosuppressive microenvironment and enhances T cell‐mediated cytotoxicity. This strategy represents a promising approach for potentiating immunotherapy in CRC by integrating innate immune activation with adaptive T cell engagement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Förderung
- China Postdoctoral Science Foundation
- Postdoctor Research Fund of West China Hospital, Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Mu, M., Chen, B., Li, H., Feng, C., Xiao, S., Fan, R., Tong, A., Chen, N., & Guo, G. (2026). A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer. Small, 22(38). https://doi.org/10.1002/smll.202514390
Vancouver
Mu M, Chen B, Li H, Feng C, Xiao S, Fan R, et al. A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer. Small. 2026;22(38). doi:10.1002/smll.202514390
BibTeX
@article{Mu2026,
author = {Mu, Min and Chen, Bo and Li, Hui and Feng, Chenqian and Xiao, Susu and Fan, Rangrang and Tong, Aiping and Chen, Nianyong and Guo, Gang},
title = {A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer},
journal = {Small},
year = {2026},
volume = {22},
number = {38},
doi = {10.1002/smll.202514390}
}
EUVIMED